Detalles de la búsqueda
1.
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Cancer
; 127(8): 1301-1310, 2021 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33289920
2.
NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1α and p27Kip1 expression in malignant melanoma and other human tumors.
Mol Carcinog
; 56(12): 2643-2662, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28762556
3.
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
Invest New Drugs
; 34(3): 355-63, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26996385
4.
Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats.
Toxicol Pathol
; 43(4): 519-29, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25274659
5.
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
J Pharmacol Exp Ther
; 349(3): 408-16, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24650937
6.
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Cancer Chemother Pharmacol
; 93(3): 177-189, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38010394
7.
Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models.
Clin Cancer Res
; 29(21): 4479-4491, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37616468
8.
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
Cancer Chemother Pharmacol
; 89(1): 49-58, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34669023
9.
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Cancer Chemother Pharmacol
; 89(5): 721-735, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35435472
10.
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 27(14): 3834-3844, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33863809
11.
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma.
Oncogenesis
; 9(9): 80, 2020 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32908120
12.
Designing phase 0 cancer clinical trials.
Clin Cancer Res
; 14(12): 3675-82, 2008 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18559582
13.
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Clin Cancer Res
; 24(23): 5830-5840, 2018 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30061364
14.
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
J Clin Oncol
; 36(16): 1594-1602, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29252124
15.
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Clin Cancer Res
; 24(4): 744-752, 2018 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29138343
16.
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.
Clin Cancer Res
; 23(21): 6421-6429, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28751440
17.
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
J Clin Pharmacol
; 57(8): 977-987, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28387939
18.
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.
PLoS One
; 12(2): e0171582, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28158293
19.
Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
Clin Cancer Res
; 23(23): 7301-7311, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28899971
20.
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Oncotarget
; 8(45): 79175-79187, 2017 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29108297